Activation of the JAK/STAT3 and PI3K/AKT pathways are crucial for IL-6 trans-signaling-mediated pro-inflammatory response in human vascular endothelial cells

Proteolytic Origin of the Soluble Human IL-6R In Vivo and a Decisive Role of N-Glycosylation

(2017) Steffen Riethmueller et al.   PLOS BIOLOGY

Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis

(2016) Michael A. Gimbrone et al.   CIRCULATION RESEARCH

Interleukin-6: Biology, signaling and strategies of blockade

(2015) Fred Schaper et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Shedding of Endogenous Interleukin-6 Receptor (IL-6R) Is Governed by A Disintegrin and Metalloproteinase (ADAM) Proteases while a Full-length IL-6R Isoform Localizes to Circulating Microvesicles

(2015) Neele Schumacher et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Intersection of mTOR and STAT signaling in immunity

(2015) Diana Saleiro et al.   TRENDS IN IMMUNOLOGY

Interleukin-6 and its receptors: A highly regulated and dynamic system

(2014) Janina Wolf et al.   CYTOKINE

Gene of the month: Interleukin 6 (IL-6)

(2014) Parvin Ataie-Kachoie et al.   JOURNAL OF CLINICAL PATHOLOGY

Targeting Interleukin-6 in Rheumatoid Arthritis

(2013) Md Yuzaiful Md Yusof et al.   DRUGS

Targeting interleukin-6 in inflammatory autoimmune diseases and cancers

(2013) Xin Yao et al.   PHARMACOLOGY & THERAPEUTICS

Interleukin-6 contributes to CNS axon regeneration upon inflammatory stimulation

(2013) M Leibinger et al.   Cell Death & Disease

Biology and significance of the JAK/STAT signalling pathways

(2012) Hiu Kiu et al.   GROWTH FACTORS

IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6

(2012) Stefan Rose-John   International Journal of Biological Sciences

Targeting Interleukin-6: All the Way to Treat Autoimmune and Inflammatory Diseases

(2012) Toshio Tanaka et al.   International Journal of Biological Sciences

The pro- and anti-inflammatory properties of the cytokine interleukin-6

(2011) Jürgen Scheller et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Interleukin-6 signalling: More than Jaks and STATs

(2011) René Eulenfeld et al.   EUROPEAN JOURNAL OF CELL BIOLOGY

Integrated safety in tocilizumab clinical trials

(2011) Michael H Schiff et al.   ARTHRITIS RESEARCH & THERAPY

Monocyte Chemoattractant Protein-1 Deficiency Protects Against Visceral Fat-Induced Atherosclerosis

(2010) Miina K. Öhman et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Cholinergic agonists regulate JAK2/STAT3 signaling to suppress endothelial cell activation

(2009) Prodyot K. Chatterjee et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Signal Transducer and Activator of Transcription 3 (STAT3) Mediates Amino Acid Inhibition of Insulin Signaling through Serine 727 Phosphorylation

(2009) Jeong-Ho Kim et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule

(2009) Miho Suzuki et al.   RHEUMATOLOGY INTERNATIONAL

Prostaglandin E1 inhibits IL-6-induced MCP-1 expression by interfering specifically in IL-6-dependent ERK1/2, but not STAT3, activation

(2008) Radoslaw M. Sobota et al.   BIOCHEMICAL JOURNAL

Atheroprotective role of interleukin-6 in diet- and/or pathogen-associated atherosclerosis using an ApoE heterozygote murine model

(2007) Monika Madan et al.   ATHEROSCLEROSIS